Deoxymethoxetamine

The following information was compiled in October 2025 and is subject to change as new research is conducted and as new information becomes available:

Description: Deoxymethoxetamine (DXME) is a novel hallucinogen. Deoxymethoxetamine is categorized as an arylcyclohexylamine and a derivative of methoxetamine, alongside methoxisopropamine (MXiPr). The first identification of deoxymethoxetamine was reported from Denmark in February of 2021.¹ Deoxymethoxetamine was first identified by our laboratory in July 2025 and confirmed after acquiring standard reference material.

Sample Source: In Collaboration with StreetCheck

Sample Appearance: Colorless plastic bag containing residue

Pharmacology: Deoxymethoxetamine is reported to be a potent N-methyl-D-aspartate (NMDA) receptor blocker with a half-maximal inhibitory concentration (IC₅₀) of 0.679 µM, similar to that of methoxetamine (MXE, IC₅₀ = 0.524 µM).²

Toxicology: Deoxymethoxetamine has not been identified in toxicology cases to date at the CFSRE.

Drug Materials: Deoxymethoxetamine has been detected in two drug materials to date at the CFSRE.

Demographics / Geographics: The drug materials originated from New England. Deoxymethoxetamine was identified alone and alongside 3-HO-PCP.

Legal Status: Deoxymethoxetamine is not currently scheduled in the United States.

Class:

Hallucinogen

Appearance:

Colorless plastic bag containing residue

Formula:

C15H21NO

MW:

231.3

[M+]:

231

[M+H]+:

232.1696

IUPAC:

2-(ethylamino)-2-(m-tolyl)cyclohexanone

Report Date:

October 28, 2025